Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression.

Huanyuan WangXiangwu ZhouZhaozhen WangTianzhu LuBaoliang LiSicong Jiang

Published in: Evidence-based complementary and alternative medicine : eCAM (2022)

Osimertinib could inhibit the expression of serum CEA and VEGF in patients with advanced non-small cell lung cancer and reduce the adverse events with significant efficacy, so it is worthy of clinical promotion and application.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
poor prognosis
vascular endothelial growth factor
endothelial cells
binding protein
long non coding rna